Intellia Therapeutics Inc [NTLA] stock prices are up 5.09% to $9.7 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The NTLA shares have gain 6.13% over the last week, with a monthly amount glided 20.65%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Intellia Therapeutics Inc [NASDAQ: NTLA] stock has seen the most recent analyst activity on November 12, 2025, when Wolfe Research downgraded its rating to a Peer Perform. Previously, Evercore ISI downgraded its rating to In-line on November 11, 2025, and kept the price target unchanged to $8. On November 07, 2025, downgrade downgraded it’s rating to Underweight but maintained its price target of $5 on the stock. RBC Capital Mkts downgraded its rating to a Sector Perform but stick to its price target of $14 on October 28, 2025. Bernstein downgraded its rating to a Mkt Perform. William Blair downgraded its rating to Mkt Perform for this stock on October 27, 2025. In a note dated October 27, 2025, Guggenheim downgraded an Neutral rating on this stock.
The stock price of Intellia Therapeutics Inc [NTLA] has been fluctuating between $5.90 and $28.25 over the past year. Currently, Wall Street analysts expect the stock to reach $18.69 within the next 12 months. Intellia Therapeutics Inc [NASDAQ: NTLA] shares were valued at $9.7 at the most recent close of the market. An investor can expect a potential return of 92.68% based on the average NTLA price forecast.
Analyzing the NTLA fundamentals
The Intellia Therapeutics Inc [NASDAQ:NTLA] reported sales of 57.53M for trailing twelve months, representing a surge of 51.27%. Gross Profit Margin for this corporation currently stands at 0.67% with Operating Profit Margin at -6.38%, Pretax Profit Margin comes in at -7.75%, and Net Profit Margin reading is -7.75%. To continue investigating profitability, this company’s Return on Assets is posted at -0.48, Equity is -0.57 and Total Capital is -0.44. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.13.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.31 points at the first support level, and at 8.92 for the second support level. However, for the 1st resistance point, the stock is sitting at 9.97, and for the 2nd resistance point, it is at 10.24.
Ratios To Look Out For
It’s worth pointing out that Intellia Therapeutics Inc [NASDAQ:NTLA]’s Current Ratio is 6.21. Also, the Quick Ratio is 6.21, while the Cash Ratio stands at 2.06. Considering the valuation of this stock, the price to sales ratio is 19.53, the price to book ratio is 1.50.
Transactions by insiders
Recent insider trading involved LEONARD JOHN M, President and CEO, that happened on Dec 11 ’25 when 88146.0 shares were sold. Officer, LEONARD JOHN M completed a deal on Dec 11 ’25 to buy 88146.0 shares. Meanwhile, EVP, Chief Scientific Officer Schultes Birgit C sold 31.0 shares on Oct 01 ’25.
